JPMS-DTC
Active not recruiting
453 enrolled
ADONIS
Completed
554 enrolled
STELLAR
Completed
335 enrolled
ROCURS
Completed
4,103 enrolled
RIFTOS MKI
Completed
667 enrolled
SORAGO-HCC
Terminated
3 enrolled
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Terminated
11 enrolled
OPTIMIS
Completed
1,676 enrolled
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Completed
3,305 enrolled
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Completed
117 enrolled
SANE
Completed
61 enrolled
SUCCESS
Completed
302 enrolled
Sorafenib in Elderly mRCC
Completed
60 enrolled
HCC Patient Preferences in Japan
Completed
120 enrolled
SECURE
Completed
106 enrolled
NEXST
Completed
205 enrolled
GIDEON
Completed
3,371 enrolled
STELLA
Completed
234 enrolled
SORINT
Completed
19 enrolled
Regulatory Post Marketing Surveillance Study on Nexavar®
Completed
2,845 enrolled
Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
Completed
1,637 enrolled
POWER-NEXT
Withdrawn
NEXTAR
Completed
20 enrolled
INSIGHT
Completed
791 enrolled
Hepatic Monitoring for Pazopanib
Completed
1 enrolled
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Completed
1 enrolled
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
Completed
1 enrolled
PONDIAC
Completed
71 enrolled
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Completed
2,840 enrolled